# US 2019/0167684 A1 · Compositions and methods for treating hcv > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2019/0167684 A1 - Document ID: US20190167684A1 - Status: Published application - Kind: A1 - Application number: 16/272,599 - Filed: 2019-02-11 - Published: 2019-06-06 - Earliest claimed: 2011-05-17 - Assignees: AbbVie Inc. - Applicants: AbbVie Inc. - Inventors: Christine A. Collins; Daniel E. Cohen; Gennadiy Koev; Preethi Krishnan; Tami J. Pilot-Matias - Web page: https://patentgrep.com/patent/US20190167684A1 ## CPC - A61K 31/513: having oxo groups directly attached to the heterocyclic ring, e.g. cytosine - A01N 37/18: containing the group —CO—N<, e.g. carboxylic acid amides or imides; Thio analogues thereof - A61K 31/4025: not condensed and containing further heterocyclic rings, e.g. cromakalim - A61K 31/427: not condensed and containing further heterocyclic rings - A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) - A61K 38/05: Dipeptides - A61K 38/21: Interferons {[IFN]} - A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca - A61P 31/12: Antivirals - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A01N: PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF (preservation of food or foodstuff A23); BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES (preparations for medical, dental or toiletry purposes which kill or prevent the growth or proliferation of unwanted organisms A61K); PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract This disclosure is directed to pharmaceutical compositions that comprise two or more therapeutic agents that, inter alia, are useful for inhibiting hepatitis C virus (HCV) and methods for inhibiting HCV by co-administering two or more anti-HCV therapeutic agents. ## Claims ### Claim 1 A combination or pharmaceutical composition comprising an amount of therapeutic agent A and an amount of therapeutic agent B, wherein therapeutic agent A is compound A or a salt thereof: and wherein therapeutic agent B is compound B or a salt thereof: ### Claim 2 (depends on 1) The combination or composition of claim 1, wherein the amount of therapeutic agent A is about 25 mg. ### Claim 3 (depends on 1) The combination or composition of claim 1, wherein therapeutic agent B is a sodium salt of compound B. ### Claim 4 (depends on 1) The combination or composition of claim 1, wherein the amount of therapeutic agent B is from about 400 to about 800 mg. ### Claim 5 (depends on 1) The combination or composition of claim 1, wherein the amount of therapeutic agent A and the amount of therapeutic agent B together constitute a therapeutically effective amount. ### Claim 6 (depends on 1) The combination or composition of claim 1, wherein the composition further comprises one or more additional therapeutic agents. ### Claim 7 (depends on 6) The combination or composition of claim 6, wherein the additional therapeutic agent is independently selected from the group consisting of ribavirin, taribavirin, and HCV inhibitor. ### Claim 8 (depends on 6) The combination or composition of claim 6, wherein the one or more additional therapeutic agents include an HCV protease inhibitor. ### Claim 9 (depends on 8) The combination or composition of claim 8, wherein the one or more additional therapeutic agents include a cytochrome P-450 inhibitor. ### Claim 10 (depends on 9) The combination or composition of claim 9, wherein the cytochrome P-450 inhibitor is ritonavir. ### Claim 11 (depends on 6) The combination or composition of claim 6, wherein the amount of therapeutic agent A, the amount of therapeutic agent B ant the amount of the additional therapeutic agent together constitute a therapeutically effective amount. ### Claim 12 A pharmaceutical composition comprising an amount of therapeutic agent A and an amount of therapeutic agent B, wherein therapeutic agent A is compound A or a salt thereof: wherein therapeutic agent B is compound B or a salt thereof: and wherein the ratio of therapeutic agent A to therapeutic agent B is about 1:20 to about 1:2000. ### Claim 13 (depends on 12) The pharmaceutical composition of claim 12, wherein the amount of therapeutic agent B is about 200 mg. ### Claim 14 (depends on 12) The pharmaceutical composition of claim 12, wherein the amount of therapeutic agent A is from about 5 mg to about 200 mg. ### Claim 15 (depends on 12) The pharmaceutical composition of claim 12, wherein the composition further comprises one or more additional therapeutic agents ### Claim 16 (depends on 15) The pharmaceutical composition of claim 15, wherein the one or more additional therapeutic agents include an HCV protease inhibitor. ### Claim 17 (depends on 16) The pharmaceutical composition of claim 16, wherein the one or more additional therapeutic agents include a cytochrome P-450 inhibitor. ### Claim 18 (depends on 12) The pharmaceutical composition of claim 12, further comprising an HCV protease inhibitor and a cytochrome P-450 inhibitor. ### Claim 19 (depends on 18) The pharmaceutical composition of claim 18, wherein the cytochrome P-450 inhibitor is ritonavir. ### Claim 20 (depends on 12) The pharmaceutical composition of claim 12, wherein therapeutic agent B is a sodium salt of compound B.